%0 Journal Article
%A Quiroga, Borja
%A Soler, María José
%A Ortiz, Alberto
%A Martínez Vaquera, Shaira
%A Jarava Mantecón, Carlos Jesús
%A Useche, Gustavo
%A Sánchez Márquez, María Gabriela
%A Carnerero, Manuel
%A Jaldo Rodríguez, María Teresa
%A Muñoz Ramos, Patricia
%A Ruiz San Millán, Juan Carlos
%A Toapanta, Nestor
%A Gracia-Iguacel, Carolina
%A Aguilar Cervera, María Cinta
%A Balibrea Lara, Noelia
%A Leyva, Alba
%A Rojas, José
%A Gansevoort, Ron T
%A de Sequera, Patricia
%A SENCOVAC Collaborative Network
%T Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.
%D 2022
%U http://hdl.handle.net/10668/19817
%X Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P  The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.
%K COVID-19
%K SARS-CoV-2
%K antibodies
%K humoral response
%K vaccine
%~